Umoja Biopharma announced a $100 million Series C round that will help the Seattle-based company further develop its CAR ...

Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme—P4HA1 prolyl hydroxylase, ...

Researchers have shown that the amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy.

Bowel cancer is the fourth most common cancer in the UK, and the second most common cause of cancer death. The disease falls ...

We recently published a list of Complete List of All AI Companies Under $2 Billion Market Cap. In this article, we are going ...

Financially risky OS Therapies has potential with mid-stage immunotherapy for osteosarcoma, but faces funding challenges and ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma ...

A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

Researchers at the Francis Crick Institute and Barts Cancer Institute, Queen Mary University of London, have shown that the amount of a protein called CD74 can indicate which people with bowel cancer ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...